A Study of the Financial Performance of Fosun Pharmaceutical Mergers and Acquisitions

DOI

10.2991/978-94-6463-748-9_28How to use a DOI?

Keywords

Fosun Pharmaceutical; Mergers and Acquisitions; Financial performance

Abstract

This article focuses on the financial performance of Fosun Pharma’s mergers and acquisitions. It analyses several of Fosun Pharma’s M&As and examines the results from the perspective of financial performance using case study and comparative analysis methods. Fosun Pharma’s profitability has improved with the launch of innovative drugs. However, it is plagued by its dependence on pandemic products. Its operational capacity has stabilised and improved through the integration of resources. Its solvency is under short-term pressure and its capital planning needs to be optimised. Its growth capacity has potential through R&D investment and market expansion. At the same time, issues such as integration risks, goodwill impairment and the impact of M&A-related industry policies need to be considered.

Copyright

© 2025 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - Jinwen Tang
PY  - 2025
DA  - 2025/07/03
TI  - A Study of the Financial Performance of Fosun Pharmaceutical Mergers and Acquisitions
BT  - Proceedings of the 2025 International Conference on Financial Risk and Investment Management (ICFRIM 2025)
PB  - Atlantis Press
SP  - 242
EP  - 253
SN  - 2352-5428
UR  - https://doi.org/10.2991/978-94-6463-748-9_28
DO  - 10.2991/978-94-6463-748-9_28
ID  - Tang2025
ER  -